Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZTC -- Ignore unavailable to you. Want to Upgrade?

To: Micawber who wrote (723)	11/11/2000 11:33:57 PM
From: Miljenko Zuanic	Respond to of 752

<<GZTC - reiterated strong buy. Rights for recombinant ATII reacquired. Discussions with potential new development partners, decision based on (GENZ) pending acquisition of (GELX). Additional studies for rhATIII expected.>> Where is hrATIII related to GELX pipeline? Nowhere! <<Anticipated changes in the clinical development plan will result in an expected 2002 filing of the Biologics License Application for rhATIII for use in managing heparin resistance during cardiopulmonary bypass surgery. Heparin is an anti-clotting therapy used during operations.>> I never liked hrATIII, but thought that mAb production has value. Now, I have to re-evaluate this perception. Never owned GZTC (actually any GZxx bios), and will not for some time. Miljenko